The odds are pretty good that they have it right this time. I added more yesterday. Successful launch of Corti was a key incentive for the Novitium team, and it's reassuring that ANIP also hired real experts who seem to have had productive contact with the FDA.
Downsides for ANIP are the debt and dilution that will be needed to close the Novitium deal, but this should be manageable.
I tend to agree with the author of the Seeking Alpha article that there are not many companies with real products and operations selling at such a discount to future prospects. However, that author did note he was not buying a lot, because he expects a market retreat that will make everything more affordable. I'm not so sure that timing the market makes sense for ANIP, and believe this is a pretty good price.
News 
Market Data 
Discover 
